A NOTE ON THE PRODUCTION OF ANTIPNEUMOCOCCUS SERA by Wadsworth, Augustus B. & Kirkbride, Mary Butler
A NOTE  ON THE PRODUCTION  OF  ANTIPNEUMOCOCCUS 
SERA. 
BY AUGUSTUS B. WADSWORTH, M.D., AND MARY BUTLER KIRKBRIDE. 
(From tke Di~M~ra of Laboratories and Researck of tke New York State Department 
of Health, Albany.) 
(Received for publication, January 5, 1917.) 
The value of homologous antipneumoeoccus serum as a therapeutic 
agent in lobar pneumonia caused by Type I  pneumocoeci, has been 
demonstrated at The Rockefeller Institute Hospital during the past 
3  years.  It is  desirable  that  the  serum should be  brought within 
reach of a  larger section of the community than has  been possible 
hitherto,  but  difficulties  in  production  and  administration  of  the 
serum have made this impossible.  The present report deals entirely 
with the production of antipneumococcus sera. 
In August,  1915, immunization of horses  to pneumococci of the 
Types I, II, and III was commenced at the farm of the New York 
State  Department  of Health near Albany,  under unfavorable  con- 
ditions  owing  to  inadequate  facilities  at  the  laboratory  and  the 
farm, and to irregularities in the injections caused by bad and occa- 
sionally impassable  roads  and  by  exposure  of  cultures  to  intense 
cold  during  the  winter  months.  None  of  the  horses  immunized 
was  under  11  years  old.  It  was  therefore  thought  that  if potent 
sera could be produced under these adverse conditions, the success 
would strengthen the belief in these methods of immunization, and 
suggest possibilities for their broader application. 
For immunization the method of ColO  with washed culture sedi- 
ment and the method of Wadsworth,  ~ using whole fresh 18 hour cul- 
tures,  were followed.  Beginning with  weekly injections,  or  injec- 
tions on  3  successive days  each week, of heated  ceils  or  cultures, 
these  were later  followed by  increasing doses  of  living organisms. 
x Cole, R., d. Exp. Med., 1912,  xvi,  644. 
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The  potency of the  sera was  tested  by protection  tests  on mice 
and  by  agglutination  reactions.  Intraperitoneal  injection  of  con- 
trol mice with  0.000001  cc.  of  the  standard  strains  of  Type I,  II, 
or  III,  received from The  Rockefeller Institute  Hospital,  and  used 
for  immunization  and  for  these  tests,  was  invariably  fatal  in  less 
than  40  hours.  Of three  horses  immunized  against  Type  I  organ- 
isms, 0.1 cc. of serum from No. 26 (culture sediment) or No. 28 (whole 
culture)  protected,  as  a  rule,  against  0.4  cc.,  and  not  infrequently 
against  0.5  cc.  of  homologous  culture.  In  three  tests  where  0.6 
cc. of culture was used, the mice did not survive.  0.1  cc.  of serum 
from No. 27  (culture sediment)  protected,  as a  rule,  against 0.2  cc., 
and  sometimes against  0.3  cc. of homologous culture. 3  Wide varia- 
tions similar  to those reported by other workers were shown in  the 
protection  tests with  Type II  sera.  0.1  cc.  of serum  from  No.  16 
(culture sediment)  or from No. 32  (whole culture) protected at times 
against  0.1  and  0.01  cc.  of  culture,  and  quite  constantly  against 
0.001  cc.; a  slightly lower protective titer was given by serum from 
Horse 29  (culture  sediment). 
Agglutination  reactions indicated  an inverse relation  between the 
agglutinating  power and the protective value of the sera,  as in each 
type the horses with a  lower protective index gave serum  having  a 
higher  agglutination  titer.  Owing  to  the  wide range  of variations 
in  agglutination  reactions,  due  to  differences in  the  density  of  the 
pneumococcus  suspensions,  satisfactory  comparison  with  previous 
agglutination  tests made by other workers is practically impossible. 
While successful active immunization  of rabbits,  sheep, and goats 
with Type III organisms (Pneumococcus  mucosus) has been reported, 
the  production  of  sera  of  sufficient  potency  to  agglutinate  fresh 
untreated  homologous organisms  or  to  confer passive immunity  on 
mice  has  apparently  been  unsuccessful  hitherto.  These  failures 
have  been  considered  to  be  due  to  the  large  mucoid  capsule  and 
tenacious  slimy  material  produced  by  and  surrounding  the  organ- 
The  serum  from Horse  27  has  since protected  0.1  cc.  against 0.4 cc. of 
culture.  Experimental tests of different methods for standardizing  the potency 
of antipneumococcus sera are in progress.  Meanwhile  in our  experience more 
satisfactory results are obtained when 0.1 cc. of Type I serum instead of 0.2 ce. 
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isms, which necessitated preliminary treatment,  such as with a weak 
acid, according to the method of Porges,  4 before agglutinations  could 
be obtained in the homologous sera. 
For  purposes  of  study  and  comparison,  the  immunization  of  a 
horse  to  Type  III  organisms  (culture  sediment)  was carried  on in 
conjunction  with  the  horses  of  Types  I  and  II. ~  The  strain  used 
for  immunization  while  at  first  less  virulent  soon  reached  that  of 
the  other  standard  types,  0.000001  cc.  killing  a  mouse  within  40 
hours.  Protection tests showed that  the serum possessed a  definite 
though  slight  and  variable  protective  action  for  mice.  0.2  cc.  of 
serum  in  one instance  protected  against  0.001  cc.  of  culture,  while 
in  other  tests  mice  receiving  the  same  amounts  of  serum  and  cul- 
ture  died in 35,  63,  or  70 hours.  The  same tests with several other 
Type III  strains  gave  similar  results. 
In  agglutination  tests  with  fresh  untreated  Type III  organisms, 
in  concentrations  of  1:1,  agglutination  was  prompt  and  striking, 
usually  showing  before  the  tubes  were  placed  in  the  water  bath. 
Within  15 to 30 minutes  agglutination  was generally  complete, and 
a loose cap had formed similar to those often seen in tests with Type 
I  and  Type  II  organisms  and  their  homologous  cultures.  While 
agglutination in concentrations of 1 : 1 and 1 : 10 occurred as promptly 
as with Type I  and Type II in their homologous sera, it was entirely 
absent  in  dilutions  above  1:40.  Undiluted  serum  obtained  5½ 
months  after  the  last  immunizing  injection  agglutinated  Type  III 
organisms  with  equal  promptness;  serum  of  1  month  later,  how- 
ever,  caused  no  reaction.  This  is  of  interest  because  the  abscess 
which had been discharging during the previous six months had healed 
meanwhile.  All  strains  of  the  mucosus  type  tested,  which  were 
morphologically  and  culturally  typical,  agglutinated  promptly with 
4  Porges, 0., Wien. klin.  Wock., 1905, xviii, 691.  yon Eisler, M., and Porges, 
0., Centr. Bakteriot., 1re Abt., Orig., 1906, xlii, 660.  I-Ianes,  F. M., Y. Exp. Med., 
1914, xix, 38. 
6  During the course of immunization a large abscess formed at the site of in- 
jection from which Type III organisms were isolated.  Later a second abscess 
of a similar nature  developed between the shoulder blades.  It would be of in- 
terezt to know the connection, if any, between these local loci of infection and 
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one  exception,  but  several  strains  which  did  not  dissolve  in  bile 
failed  to  agglutinate.  In  a  number of instances  Type III organ- 
isms, which might readily have been classified as Type IV, owing to 
apparent  absence  in  inoculated  mice  of  the  characteristic  sticky 
peritoneal exudate and to the unusually small capsule of the organ- 
isms,  were  agglutinated promptly in Type III serum.  Conversely, 
absence  of agglutination in  Type III  serum made possible prompt 
exclusion  from  the  Type III  group  of pneumococci obtained from 
the  peritoneum of  mice,  in  which a  slightly viscous exudate  was 
apparently present.  The  serum  is,  therefore,  of distinct value  in 
the diagnosis of pneumococcus types and should be used as a routine 
procedure together with  the sera  of Types I  and II. 
SUMMARY. 
Horses  immunized to  Type  I  pneumococci developed serum, 0.1 
cc. of which protected against 0.5 cc. of a  virulent culture, 0.000001 
cc.  of which killed mice in less than 40 hours.  Protective tests of 
serum from horses immunized to Type II organisms varied, 0.1  cc. 
protecting, however, in certain instances against 0.1  and 0.01  cc.  of 
virulent homologous culture.  Types I  and  II sera obtained in our 
experiments with culture sediment and whole culture  did not vary 
markedly for  a  given type  and  corresponded closely in  their pro- 
tective  titer  with  samples  of sera  received from  The  Rockefeller 
Institute Hospital.  It is therefore evident that the following mini- 
mum standard  of 0.1  cc. of serum to protect mice against at  least 
0.2  cc.  of  virulent  cultures  can  and  should  be  maintained when 
serum is to be used for the treatment  of cases.  By  further  study 
and  comparison  of  these different methods  of  immunization it  is 
hoped that sera of greater potency may be produced, but as yet this 
has only been accomplished in exceptional instances. 
A  horse  immunized with  Type  III  (Pneumococcus mucosus) de- 
veloped serum having a  slight degree of protection for mice against 
the  corresponding organisms.  This  serum  was  sufficiently potent, 
however,  to  cause  prompt and  complete agglutination when  com- 
bined  with  fresh  untreated  homologous organisms,  thus  avoiding 
the  preliminary  treatment  to  remove  the  capsule  which  has  pre- 
viously been held necessary.  As a  diagnostic aid in the differentia- 
tion of pneumococcus strains, the serum has proved of distinct value. 